

Friso MUM, the activity of a helath supplement during pregnancy and lactation.

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON25238

Source

NTR

Brief title

MUM

Health condition

(Neurological development)

Sponsors and support

Primary sponsor: Friesland Foods, Leeuwarden. Department "Friso Kindervoeding" (Nutrition)

Intervention

Outcome measures

Primary outcome

Neurological Development of the baby (Neurological Optimality Score and General Movements).

Secondary outcome

1. Mood, cognitive functioning and sleeping rhythm of the mother;
2. LCP status in red blood cells of mother (16th and 36th week) and child (12 weeks after birth), umbilical cord, breast milk (2 and 12 weeks after birth).

Study description

Background summary

Healthy pregnant women are included prior to the 16th week of pregnancy and are followed till 12 weeks postpartum. During the whole period they have to take the supplement provided and the effect on neurological development is judged.

Study objective

DHA and AA during pregnancy shall lead to a better neurological development of the baby and possibly to better mood, cognitive functioning and sleeping rhythm of the mother.

Study design

N/A

Intervention

Everybody receives a multivitamin supplement (designed for pregnant women).

Next to that we compare placebo vs DHA vs DHA/AA.

Contacts

Public

University Medical Center Groningen (UMCG), Department of Pathology and Laboratory Medicine, Postblok CMC-V-1 floor,
P.O. box 30001
Saskia A. Goor, van
Hanzeplein 1
Groningen 9700 RB
The Netherlands
+31 (0)50 3610399

Scientific

University Medical Center Groningen (UMCG), Department of Pathology and Laboratory Medicine, Postblok CMC-V-1 floor,
P.O. box 30001
Saskia A. Goor, van
Hanzeplein 1
Groningen 9700 RB
The Netherlands
+31 (0)50 3610399

Eligibility criteria

Inclusion criteria

1. Apparently healthy pregnant women;
2. Para 0 or 1;
3. Inclusion should take place prior to the 16th week of pregnancy.

Exclusion criteria

1. Hyperemesis Gravidarum
2. Vegetarian or Vegan;
3. Pregnant with twins;
4. Diabetes Mellitus type 1;
5. Usage of health supplements with fatty acids, tryptophan or melatonin.

Study design

Design

Study type: Interventional
Intervention model: Parallel

Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-11-2004
Enrollment:	300
Type:	Actual

Ethics review

Positive opinion	
Date:	12-09-2005
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL328
NTR-old	NTR366
Other	: N/A
ISRCTN	ISRCTN58176213

Study results

Summary results

N/A